Cancer is a brutal disease and one of the leading causes of death in the developed world. Worldwide, the disease struck more than 17 million people in 2018 with that figure expected to mushroom.
One company that is doing its part in the fight against cancer is NovoCure Ltd (NASDAQ: NVCR).
Founded in 2000, NovoCure has developed a cancer therapy called tumour treating fields, which inhibits tumour growth and may causes cancer cells to die.
In this article, I take a look at the medical research behind its technology and whether NovoCure is a potential multi-bagger.